You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in.


Medicalindependent.ie is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.


The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline
 
[the_ad_placement id="main-ldb-public"]
[the_ad_placement id="main-ldb-mobile-public"]

You are reading 1 of 2 free-access articles allowed for 30 days

Gene therapy for CF shows beneficial effect on lung function

By Dermot - 06th Jul 2015 | 4 views

The technique replaces the defective gene response for CF by using inhaled molecules of DNA to deliver a normal working copy of the gene to lung cells.

“Patients who received the gene therapy showed a significant, if modest, benefit in tests of lung function compared with the placebo group and there were no safety concerns,” said senior author Prof Eric Alton from the National Heart and Lung Institute, Imperial College London. “Whilst the effect was inconsistent, with some patients responding better than others, the results are encouraging.”

CF is a rare inherited disease caused by mutations in a single gene called cystic fibrosis transmembrane conductance regulator (CFTR) and affects 1 in every 2,500 new-borns in the UK and over 90,000 people worldwide. Ireland has the highest incidence (per head of population) of CF in the world, with around 1,200 children and adults affected by the condition.

Scientists have discovered around 2000 CFTR mutations so far. These mutations make the lining of the lungs secrete unusually thick mucus. This leads to recurrent life-threatening lung infections, which result in lung damage that causes 90 per cent of deaths in people with cystic fibrosis.

Since the discovery of the genetic basis for cystic fibrosis in 1989, scientists have developed a variety of viral and non-viral vector systems for delivering a corrected CFTR gene back into lung cells. Despite expectations of a rapid breakthrough, no CF gene therapy trial so far has been able to show long-term clinical improvement.

Coordinated by the UK Cystic Fibrosis Gene Therapy Consortium , the two-year study involved 136 CF patients aged 12 years or older from across the UK. Participants were randomly assigned to either 5ml of nebulised (inhaled) pGM169/GL67A (gene therapy) or saline (placebo) at monthly intervals over 1 year. Lung function was evaluated using a common clinical measure of the volume of air forcibly exhaled in one second (FEV1).

After a year of treatment, in the 62 patients who received the gene therapy, FEV1 was 3.7 per cent greater compared to placebo. This was a result of stabilisation of respiratory function rather than an improvement. However, the effects were inconsistent, with some patients responding better than others. In particular, in the half of patients with the worst lung function at the start of the study, there was a doubling of the treatment effect, with changes in FEV1 of 6.4 per cent.

Overall, the gene therapy was well tolerated and patients in the treatment and placebo groups experienced similar rates of adverse events.

According to senior co-author Prof Stephen Hyde from the Gene Medicine Research Group at the University of Oxford, “Stabilisation of lung disease in itself is a worthwhile goal. We are actively pursuing further studies of non-viral gene therapy looking at different doses and combinations with other treatments, and more efficient vectors.”

Senior co-author Dr Alastair Innes from Western General Hospital, Edinburgh, UK added that publication of this trial is a landmark for CF patients. He expressed gratitude to the many patients across the UK “who gave their time and effort to participate and make this collaborative venture a success”.

 

Leave a Reply

[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]
Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

[the_ad_placement id="main-mpu-public"]
Most Read
[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]